1. The Art of Drug Discovery Flashcards

1
Q

First-in-class drug

A

targets a protein that has not been targeted before by another drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

The FDA approved ____ novel drugs in ____, the fewest to pass regulatory scrutiny since 2016

A

37

2022

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Takes about ___ years for molecule to be approved

A

15

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

_____ prescription drugs marketed in North America

A

1000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Discovery/ Preclinical Testing

A
  1. lab & animal studies
  2. Asses safety, biological activity and formulations
  3. 5000 compounds evaluated
  4. 6.5 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Phase 1

A
  1. 20-100 healthy volunteers
  2. Determine safety and dosage
  3. 5 compounds
  4. 1.5 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Phase 2

A
  1. 100-500 patient volunteers
  2. Evaluate effectiveness & look for side effects
  3. 5 compounds
  4. 2 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Phase 3

A
  1. 1000-5000 patient volunteers
  2. Confirm effectiveness, monitor adverse reactions from long term use
  3. 5 compounds
  4. 3.5 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

FDA review and approval

A
  1. 1.5 years
  2. one compound approved
  3. review and approval process
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Phase 4

A

(whole process 15 years total)
1. additional post marketing testing required by FDA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

World Health Organization takes into account…

A
  1. disease prevalence
    1. impact on disability-adjusted life years, DALYs
    2. public health, community health
    3. Evidence of efficacy
    4. evidence that the drug is safe
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Highest proportion of drugs improved in which therapeutic area?

A
  1. Oncology
  2. Infectious diseases
  3. Neurology
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Who decides medical needs?

A
  • FDA (US)
  • Health Canada (Canada)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Drug target

A

a molecule (usually a protein) involved in the disease, that the drug binds to, often inactivation the molecule

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What makes a protein “druggable”?

A

good protein structure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Phase 1 Clinical Trials Purpose

A

–Determine a safe drug dose

17
Q

Pharmacokinetics

A

what happens to the drug in the body, how the drug moves in the body

18
Q

Phase 1 Clinical Trials Design

A

Usually dose-escalation. Start low, increase dose (Cautious)

19
Q

Phase 1 Clinical Trials Subjects

A

– Normal volunteers usually
– Sometimes patients with the disease (cancer)
– Must obtain informed consent from subjects

20
Q

Placebos

A

Placebos look like real pills but contain no active drug ingredient (controls for the “placebo effect”) is the expected response to taking a drug, (real brain circuitry involved)

21
Q

Phase 2 Clinical Trials Purpose

A

To obtain preliminary information on the efficacy of the drug

22
Q

Phase 2 Clinical Trials Design

A

Compare treated individuals to control individuals

23
Q

Phase 2 Clinical Trials Subjects

A

Patients with the disease

24
Q

Efficacy

A

does the drug work to treat the medical condition?

25
Q

Single-blind trials

A

subjects don’t know who is getting treatment and who is getting placebo

26
Q

Double-blind trials

A

neither subjects nor investigators know (Computer records – we ultimately do know who received which treatment)- MOST COMMON

27
Q

Phase 3 Clinical trials Purpose

A

To compare efficacy of the new treatment with the standard regimen

28
Q

Phase 3 Clinical trials Design

A

Usually randomized control

29
Q

Phase 3 Clinical trials Subjects

A

Patients with the disease

30
Q

Informed Consent

A

the process of understanding what you are agreeing (consent) to

31
Q

Generic drugs

A

same chemical, off-patent
ie: Plan-B & contingency one

32
Q

Patent protection

A

20 years following filing (gives the manufacturer a monopoly for this amount of time- usually files for patent during discovery phase)

33
Q

Cost and time of developing a drug

A

Costs about >2 billion dollars & takes about 15 years